AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event
Announcing Sustainability Benchmarking Initiative and New Gen-AI Features of Pharma.AI Platform CAMBRIDGE, Mass., July 24, 2024 /PRNewswire/ -- Insilico Medicine...
Cancer
Credit Unions Raise Over $1.5 Million To Help Move Kids Out of Hospitals and Onto Playgrounds
In a powerful display of unity, First Tech joined forces with fellow credit unions and industry partners to support children's...
Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity
CHICAGO, IL / ACCESSWIRE / July 24, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the...
ImPact Biotech Receives a €13.5M Investment Commitment from the European Innovation Council’s Accelerator Program
TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular...
Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces...
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollmentFOSTER CITY, Calif., July 24, 2024 (GLOBE...
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following...
Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate)...
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to...
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis Lusvertikimab...
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
MELBOURNE, Australia, July 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the...
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update...
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program
Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX:...
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across...
50% Imaging Error Rate in Clinical Trials Discussed by Expert Panelists from 5 NCI-Designated Cancer Centers
Data points to a broader industry-wide imaging accuracy crisisCHICAGO, IL / ACCESSWIRE / July 23, 2024 / Yunu, a provider...
David Rubenstein Joins Moderna’s Board of Directors
Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen BerensonCo-founder...
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics...